Labcorp Diagnostics, Morrisville, NC, USA; Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Labcorp Diagnostics, Morrisville, NC, USA.
Lancet Healthy Longev. 2023 Feb;4(2):e72-e82. doi: 10.1016/S2666-7568(23)00001-6.
Complex and incompletely understood metabolic dysfunction associated with inflammation and protein-energy wasting contribute to the increased mortality risk of older patients and those with chronic organ diseases affected by cachexia, sarcopenia, malnutrition, and frailty. However, these wasting syndromes have uncertain relevance for patients with cardiovascular disease or people at lower risk. Studies are hampered by imperfect objective clinical assessment tools for these intertwined metabolic malnutrition and inflammation syndromes. We aimed to assess, in two independent cohorts of patients who underwent cardiac catheterisation, the mortality risk associated with the metabolic vulnerability index (MVX), a multimarker derived from six simultaneously measured serum biomarkers plausibly linked to these dysmetabolic syndromes.
In this prospective, longitudinal, observational study, we included patients aged ≥18 years recruited into the CATHGEN biorepository (Jan 2, 2001, to Dec 30, 2011) and the Intermountain Heart Collaborative Study (Sept 12, 2000, to Sept 21, 2006) who underwent coronary angiography and had clinical nuclear magnetic resonance metabolomic profiling done on frozen plasma obtained at catheterisation. We aggregated six mortality risk biomarkers (GlycA, small HDL, valine, leucine, isoleucine, and citrate concentrations) into sex-specific MVX multimarker scores using coefficients from predictive models for all-cause mortality in the CATHGEN cohort. We assessed associations of biomarkers and MVX with mortality in both cohorts using Cox proportional hazards models adjusted for 15 clinical covariates.
We included 5876 participants from the CATHGEN biorepository and 2888 from the Intermountain Heart study. Median follow-up was 6·2 years (IQR 4·4-8·9) in CATHGEN and 8·2 years (6·9-9·2) in the Intermountain Heart study. The six nuclear magnetic resonance biomarkers and MVX made strong, independent contributions to 5-year mortality risk prediction in both cohorts (hazard ratio 2·18 [95% CI 2·03-2·34] in the CATHGEN cohort and 1·67 [1·50-1·87] in the Intermountain Heart cohort). CATHGEN subgroup analyses showed similar MVX associations in men and women, older and younger individuals, for death from cardiovascular or non-cardiovascular causes, and in patients with or without multiple comorbidities.
MVX made a dominant contribution to mortality prediction in patients with cardiovascular disease and in low-risk subgroups without pre-existing disease, suggesting that metabolic malnutrition-inflammation syndromes might have a more universal role in survival than previously thought.
Labcorp.
与炎症和蛋白质能量消耗相关的复杂且不完全了解的代谢功能障碍导致老年患者和患有恶病质、肌少症、营养不良和衰弱的慢性器官疾病的患者的死亡风险增加。然而,这些消耗综合征对于心血管疾病患者或风险较低的人群的相关性尚不确定。由于这些相互交织的代谢性营养不良和炎症综合征缺乏完善的客观临床评估工具,研究受到了阻碍。我们旨在通过两种独立的接受心脏导管检查的患者队列来评估代谢脆弱性指数(MVX)与死亡率之间的相关性,MVX 是一种源自六个同时测量的血清生物标志物的多指标,这些生物标志物与这些代谢异常综合征有一定的联系。
在这项前瞻性、纵向、观察性研究中,我们纳入了 2001 年 1 月 2 日至 2011 年 12 月 30 日期间在 CATHGEN 生物库(CATHGEN biorepository)招募的年龄≥18 岁的患者,以及 2000 年 9 月 12 日至 2006 年 9 月 21 日期间在 Intermountain Heart 协作研究(Intermountain Heart Collaborative Study)中接受冠状动脉造影且在导管检查时采集了冷冻血浆的患者。我们使用 CATHGEN 队列中全因死亡率预测模型的系数,将六种与死亡率相关的生物标志物(GlycA、小 HDL、缬氨酸、亮氨酸、异亮氨酸和柠檬酸浓度)聚合为性别特异性 MVX 多指标评分。我们使用 Cox 比例风险模型评估了两个队列中的生物标志物和 MVX 与死亡率之间的相关性,该模型调整了 15 个临床协变量。
我们纳入了来自 CATHGEN 生物库的 5876 名参与者和来自 Intermountain Heart 研究的 2888 名参与者。CATHGEN 队列的中位随访时间为 6.2 年(四分位距 4.4-8.9),Intermountain Heart 研究的中位随访时间为 8.2 年(6.9-9.2)。在两个队列中,六种磁共振生物标志物和 MVX 对 5 年死亡率风险预测均有较强的独立贡献(CATHGEN 队列的危险比为 2.18[95%CI 2.03-2.34],Intermountain Heart 队列的危险比为 1.67[1.50-1.87])。CATHGEN 亚组分析显示,MVX 在男性和女性、年龄较大和较小的个体、心血管或非心血管原因导致的死亡以及有或没有多种合并症的患者中具有相似的相关性。
MVX 对心血管疾病患者和无预先存在疾病的低风险亚组的死亡率预测有主要贡献,这表明代谢性营养不良-炎症综合征在生存方面的作用可能比以前认为的更为普遍。
Labcorp。